一分钟看懂
这是一项关于黑色素瘤的II 期研究，登记的药物或干预包括GB1211；Pembrolizumab；Placebo，当前状态为研究进行中，已停止招募。登记地点显示中国Portland有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
GB1211；Pembrolizumab；Placebo · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Providence Portland Medical Center · Portland
公开的入选条件
- * Patients with unresectable or metastatic melanoma including unknown primary or mucosal melanomas. Histological confirmation of melanoma will be required by previous biopsy or cytology. Patients with recurrent or metastatic head and neck squamous cell carcino
- * Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has been at least 6 months since the last anti-PD-1 or PD-L1 dose, they meet all other eligibility criteria and progression of malignancy has been documented on imaging. Progres
- * Patients must be ≥ 18 years of age.
- * ECOG performance status of 0-2.
- * Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearin
- * No active bleeding.
- * Anticipated lifespan greater than 12 weeks.
- * Patients must sign a study-specific consent document.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05913388；登记信息更新于 2026-09-16。